SPEVIGO (Boehringer Ingelheim Pty Ltd)
Product name
SPEVIGO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
226 (255 working days)
Active ingredients
spesolimab
Registration type
NCE/NBE
Indication
SPEVIGO is indicated for the treatment of flares in adult patients with generalised pustular psoriasis.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.